3B BlackBio Dx concludes investor meeting with Capri Global Holdings

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights
  • 3B BlackBio Dx concluded one-on-one investor call with Capri Global Holdings
  • Meeting held on September 11, 2026, from 11:00 am to 12:00 pm India Time
  • Company reiterated Q1-FY27 investor presentation details during the session
  • No unpublished price-sensitive information was shared with the investor
powered bylight_fuzz_icon
50156633

*this image is generated using AI for illustrative purposes only.

3B BlackBio Dx Limited concluded its scheduled one-on-one investor interaction with Capri Global Holdings on Friday, September 11, 2026. The virtual meeting ran from 11:00 am to 12:00 pm India Time.

The company disclosed the outcome pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Management confirmed that only information available in the public domain was discussed. No unpublished price-sensitive information was shared during the session.

Meeting Details

The interaction focused on the company’s recent financial performance and strategic outlook. The company reiterated details from its Investor Presentation for Q1-FY27, which was previously intimated to stock exchanges vide Ref. No. P-66/2026-27/27 dated August 13, 2026.

Parameter Details
Date September 11, 2026
Time 11:00 am to 12:00 pm India Time
Counterparty Capri Global Holdings, Mumbai
Mode Virtual Investor Conference Call
Type One-on-One

Presentation Material

For this meeting, the company utilized the Investor Presentation of Q1-FY27. This document was shared with investors following the declaration of financial results for the quarter ended June 30, 2026.

The disclosure was signed by Nikhil Kuber Dubey, Whole Time Director of 3B BlackBio Dx Limited (formerly Kilpest India Limited). The company noted that the date and time of such interactions are subject to change due to exigencies on the part of the investor or the company.

Historical Stock Returns for 3B BlackBio DX

1 Day5 Days1 Month6 Months1 Year5 Years
+5.40%+24.91%+18.68%+31.38%+31.38%+31.38%

How might the strategic outlook presented in the Q1-FY27 deck influence 3B BlackBio Dx's valuation multiples compared to its diagnostic peers?

What specific growth drivers or operational milestones should investors monitor in Q2-FY27 to validate the management's forward-looking statements?

Given the rebranding from Kilpest India Limited, how is the market perceiving the company's transition towards a pure-play diagnostics business?

3B BlackBio Dx sets AGM for Sept 29; declares ₹5 dividend

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • 3B BlackBio Dx schedules 54th AGM for September 29, 2026
  • Final dividend of ₹5 per equity share declared for FY26
  • E-voting window open from September 26 to September 28, 2026
  • Annual Report accessible via company website for non-email registered holders
powered bylight_fuzz_icon
50316111

*this image is generated using AI for illustrative purposes only.

3B BlackBio Dx has scheduled its 54th Annual General Meeting for September 29, 2026. The meeting will convene to adopt the audited financial statements for FY26 and declare a final dividend of ₹5 per equity share.

The company, formerly known as Kilpest India Limited, will hold the meeting via Video Conferencing or Other Audio Visual Means at 11:30 am IST. Shareholders on record as of September 22, 2026, will be eligible for the dividend payout and voting rights.

Key Agenda Items

The ordinary business includes the adoption of standalone and consolidated financial statements for the year ended March 31, 2026. The Board recommends the final dividend out of current profits, subject to member approval.

Special business items focus on governance and audit compliance:

  • Reappointment of Mrs. Mithla Dubey as a Non-Executive Director liable to retire by rotation.
  • Ratification of remuneration for Cost Auditors Sanjay Kasliwal & Associates.

Director Reappointment

Mrs. Mithla Dubey (DIN: 03597415), aged 79, seeks reappointment as a Non-Executive Director. Under SEBI Listing Regulations, a special resolution is required for directors aged 75 or above. She serves as a promoter and woman director, holding 10,59,770 equity shares as of March 31, 2026.

Audit Remuneration

The Board seeks ratification for a remuneration of ₹50,000 payable to Sanjay Kasliwal & Associates for conducting the cost audit for the financial year ending March 31, 2027. This appointment follows a recommendation by the Audit Committee.

E-Voting and Book Closure

Pursuant to Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has provided a remote e-voting facility. The cut-off date for determining eligibility is Tuesday, September 22, 2026.

The remote e-voting period commences on Saturday, September 26, 2026, at 9.00 am and ends on Monday, September 28, 2026, at 5.00 pm IST.

Event Date Time
Record Date September 22, 2026 -
E-Voting Start September 26, 2026 9.00 am
E-Voting End September 28, 2026 5.00 pm
AGM Date September 29, 2026 11.30 am

The Register of Members and Share Transfer Books will remain closed from Wednesday, September 23, 2026, to Tuesday, September 29, 2026 (both days inclusive) for the purpose of the AGM and dividend payment.

Annual Report Access

In compliance with Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has sent letters to shareholders who have not registered their email addresses. These shareholders can access the Annual Report for the Financial Year 2025-26 via the company’s website at www.kilpest.com under Investor Info > 3B BlackBio Dx Limited Annual Report 2026. The report is also available on the BSE website.

Historical Stock Returns for 3B BlackBio DX

1 Day5 Days1 Month6 Months1 Year5 Years
+5.40%+24.91%+18.68%+31.38%+31.38%+31.38%

How might the reappointment of a 79-year-old promoter director impact investor confidence regarding long-term succession planning and governance stability?

What strategic initiatives is 3B BlackBio Dx prioritizing in FY27 given the modest final dividend of ₹5 per share?

Will the ratification of cost auditor remuneration signal any upcoming changes in manufacturing efficiency or regulatory compliance costs for the company?

More News on 3B BlackBio DX

1 Year Returns:+31.38%